Palvella Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum
Palvella Therapeutics, Inc. (PVLA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum of 120.89% for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-31.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum · last filed 2021-03-31
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2017-09-30 was 78.89%, a 5.02% increase year-over-year.
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2017-06-30 was 78.89%, a 4.45% increase year-over-year.
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2017-03-31 was 75.13%, a 1.14% decline year-over-year.
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2016-09-30 was 75.12%, a 2.30% increase year-over-year.
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2020 was 120.89%.
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2017 was 78.90%, a 3.82% increase from fiscal 2016.
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2016 was 76.00%, a 1.24% increase from fiscal 2015.
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2015 was 75.07%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 12 month |
|---|---|---|---|---|
| 2020-12-31 | 120.89% 10-K · filed 2021-03-31 | |||
| 2017-12-31 | 78.90% 10-K · filed 2018-03-15 | |||
| 2017-09-30 | 78.89% 10-Q · filed 2017-11-13 | 78.89% 10-Q · filed 2017-11-13 | ||
| 2017-06-30 | 78.89% 10-Q · filed 2017-08-11 | 78.89% 10-Q · filed 2017-08-11 | ||
| 2017-03-31 | 75.13% 10-Q · filed 2017-05-15 | |||
| 2016-12-31 | 76.00% 10-K · filed 2018-03-15 | |||
| 2016-09-30 | 75.12% 10-Q · filed 2017-11-13 | 76.00% 10-Q · filed 2017-11-13 | ||
| 2016-06-30 | 75.53% 10-Q · filed 2017-08-11 | 76.00% 10-Q · filed 2017-08-11 | ||
| 2016-03-31 | 76.00% 10-Q · filed 2017-05-15 | |||
| 2015-12-31 | 75.07% 10-K · filed 2017-03-30 | |||
| 2015-09-30 | 73.43% 10-Q · filed 2016-11-10 | 75.07% 10-Q · filed 2016-11-10 | ||
| 2015-06-30 | 75.07% 10-Q · filed 2016-08-11 | 75.07% 10-Q · filed 2016-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |